chevron_leftBack
As of 24 April 2025, PharmaEssentia Corp. has a market cap of $5.1B USD, ranking #2805 globally and #55 in Taiwan. It ranks #247 in the Healthcare sector, and #37 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$5.1BUSD
165.85B TWD
Enterprise Value
$4.48BUSD
145.77B TWD
Revenue (TTM)
$299.13MUSD
9.73B TWD
EBITDA (TTM)
$56.74MUSD
1.85B TWD
Net Income (TTM)
$91.12MUSD
2.97B TWD
EBITDA Margin
19%
Profit Margin
30%
PE Ratio
56.1
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Ko-Chung Lin
open_in_new
Employees
131
Founded
1990
Website
pharmaessentia.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 3.1% | 1.6% | -14% | -28% | -22% | 73% |
Upcoming Earnings
Earnings Date
Mon, May 12
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
6446
藥華醫藥股份有限公司
ISIN: TW0006446008
Shares Out.:
Shares Outstanding:
333.042M1
Shares Float:
294.813M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
498.00 TWD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About PharmaEssentia Corp.
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia. In addition, it focuses on the drug research and development programs in the areas of hematology, infectious disease, and oncology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.
